Innogenetics Weighs Solvay’s Sweetened Takeover Offer Trumping Gen-Probe
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe says it will not increase its offer for Belgian molecular diagnostics firm Innogenetics now that drug maker Solvay has submitted a higher bid, worth $316 million for all of Innogenetics' outstanding shares
You may also be interested in...
Gen-Probe Adds European Reach Through $132 Million Tepnel Acquisition
Gen-Probe will double its European sales force and expand its existing molecular diagnostics portfolio through the $132.2 million purchase of UK-based Tepnel Life Sciences
Gen-Probe Adds European Reach Through $132 Million Tepnel Acquisition
Gen-Probe will double its European sales force and expand its existing molecular diagnostics portfolio through the $132.2 million purchase of UK-based Tepnel Life Sciences
Financings In Brief
Abiomed raises $41 million: Cardiac assist device maker nets $41.7 million from a stock offering of 2.4 million common shares at $17.38 each, completed Aug. 22. The proceeds will go toward expanded distribution capability, R&D, clinical trials and "general corporate purposes," the firm says. On July 30, the Danvers, Mass. company announced plans to expand manufacturing capacity in Ireland for its Impella 2.5 percutaneously implanted cardiac assist device, which received 510(k) clearance June 2 for partial circulatory support for up to six hours (1"The Gray Sheet" June 9, 2008, p. 20). Morgan Stanley was underwriter for the stock offering